Activated protein C (APC) inactivates activated factor V (FVa) and moderates FVIIIa by restricting FV cofactor function. Emicizumab is a humanized anti-FIXa/FX bispecific monoclonal antibody that mimicks FVIIIa cofactor function. In recent clinical trials in haemophilia A patients, once-weekly subcutaneous administration of emicizumab was remarkably effective in preventing bleeding events, but the mechanisms controlling the regulation of emicizumab-mediated haemostasis remain to be explored. We investigated the role of APC-mediated reactions in these circumstances. APC dose-dependently depressed thrombin generation (TG) initiated by emicizumab in FVIII-deficient plasmas, and in normal plasmas preincubated with an anti-FVIII antibody (FVIII-depleted). FVIIIa-independent FXa generation with emicizumab was not affected by the presence of APC, protein S and FV. The results suggested that APCinduced down-regulation of emicizumab-dependent TG was accomplished by direct inactivation of FVa. The addition of APC to emicizumab mixed with FVIII-depleted FV-deficient plasma in the presence of various concentrations of exogenous FV demonstrated similar attenuation of TG, irrespective of specific FV concentrations. Emicizumab-related TG in FVIII-depleted FV Leiden plasma was decreased by APC more than that observed with native FV Leiden plasma. The findings indicated that emicizumab-driven haemostasis was down regulated by APC-mediated FVa inactivation in plasma from haemophilia A patients without or with FV defects.
Factor (F)V contributes to opposing mechanisms in the regulation of blood coagulation (Dahlb€ ack, 2016) . FV is converted to its active form (FVa) by limited proteolytic cleavage by thrombin. FVa functions as a cofactor for FXa in the prothrombinase complex, which catalyses the conversion of prothrombin to thrombin on phospholipid (PL) membranes (Foster et al, 1983) . The potential development of a hypercoagulable state is controlled by activated protein C (APC) together with protein S (PS). In these reactions, FVa is rapidly inactivated by proteolytic cleavage at Arg306, Arg506, and Arg679 by APC/PS (Walker et al, 1979; Suzuki et al, 1983) . Cleavage at Arg506 predominantly takes place first, and together with subsequent cleavage at Arg306, initiates near complete loss of FVa activity. Therefore, any defect of one or more of the cleavage reactions significantly affects the processes of APC-induced inactivation (Nicolaes et al, 1995; Gale et al, 2002) .
An alternative coagulation function of FV is as a cofactor of APC in the inactivation of activated FVIII (FVIIIa) (Dahlb€ ack, 2016) . During this process, FV functions as an anti-coagulant cofactor in the presence of PS, resulting in acceleration of FVIIIa inactivation by proteolytic cleavage at Arg336 (O'Brien et al, 2000; Gale et al, 2008) . This anti-coagulant activity of FV is mediated by a product of APCinduced proteolysis, prior to cleavage by thrombin. Cleavage of FV at Arg506, with the attached B domain, is essential for the anti-coagulant activity of FV (Thorelli et al, 1999) , whereas cleavage at Arg306 appears to contribute less to this mechanism (Lu et al, 1996) . Any molecular defect of these cleavage reactions confers an APC-resistance phenotype (Dahlb€ ack et al, 1993) .
FVIII, a plasma protein that is deficient or defective in individuals with haemophilia A, functions as a cofactor in the tenase complex, which is responsible for PL-dependent FXa generation by FIXa (Mann et al, 1990) . The catalytic efficiency of FVIII in the tenase complex is enhanced by thrombin-induced proteolysis to FVIIIa (Eaton et al, 1986) . Following this reaction, APC inactivates FVIIIa by initial proteolytic cleavage at Arg336 and by secondary cleavage at Arg562 (Fay et al, 1991) . However, the relative contributions of FVa inactivation and FVIIIa inactivation in APC-related mechanisms remain to be fully characterised.
Recent reports have shown that the recombinant humanized bispecific monoclonal antibody emicizumab (also termed ACE910), functions as a FVIIIa-mimetic by binding simultaneously to FIXa and FX (Kitazawa et al, 2012; Sampei et al, 2013) . The antigenicity of emicizumab is different from that of FVIII and therefore could be expected to be therapeutically effective, irrespective of the presence of FVIII inhibitors . In this context, current phase 1/2 extension and phase 3 clinical studies demonstrated that once-weekly subcutaneous administration of emicizumab was well tolerated, and substantially reduced the annualized bleeding rates in haemophilia A patients both with and without inhibitors (Oldenburg et al, 2017; Shima et al, 2017) . The mechanism(s) of enhanced haemostatic function mediated by emicizumab has been characterized (Kitazawa et al, 2012 , but the role of APC-mediated down-regulation in these reactions remains to be fully explored.
In the present study, we investigated APC-dependent regulation haemostasis reactions mediated by emicizumab independent of FVIII/FVIIIa, using a thrombin generation (TG) assay together with a purified FXa generation assay. In particular, we demonstrated that emicizumab-driven haemostasis in plasma from patients with haemophilia A was downregulated by APC-induced inactivation of FVa. Our findings provide novel information on the potentially significant regulation of haemostasis in patients with haemophilia A treated with emicizumab.
Materials and methods

Reagents
Emicizumab, a recombinant humanized bispecific IgG4 antibody to FIXa and FX, was produced in a Chinese hamster ovary cell line . FV-deficient plasma and FVIII-deficient plasma (George King, Overland Park, KS, USA), FV Leiden plasma (Trina Bioreactive, Zurich, Switzerland), plasma-derived (pd-)APC, FV and PS (Haematologic Technologies Inc., Essex Junction, VT, USA), recombinant hirudin (Calbiochem, San Diego, CA, USA), recombinant human tissue factor (TF) (Innovin â ; Dade, Marburg, Germany), ellagic acid (Elg; Sysmex, Kobe, Japan), a thrombinspecific fluorogenic substrate (Z-Gly-Gly-Arg-AMC, Bachem, Bubendorf, Switzerland) and FXa substrate S-2222 (Chromogenix, Milan, Italy) were purchased from the indicated vendors. PL vesicles containing 10% phosphatidylserine, 60% phosphatidylcholine and 30% phosphatidylethanolamine (Sigma-Aldrich, St Louis, MO, USA) were prepared using Noctylglucoside (Okuda & Yamamoto, 2004) . Immunoglobulin G (IgG) fractions of patient's plasma with FVIII inhibitor (recognizing both epitopes within A2 and C2 domains) (Shima et al, 1993) were prepared by affinity chromatography using protein G Sepharose. Pooled normal plasma (PNP) was prepared from 20 normal healthy individuals. Blood samples were collected in plastic tubes containing 3Á2% sodium citrate at a 9:1 ratio. All plasma samples were stored at À80°C and thawed at 37°C immediately prior to the assays. The plasma collection in this study was performed under the approval of the Institutional Review Boards of Nara Medical University (Nara, Japan) and Chugai Pharmaceutical Co., Ltd. (Kamakura, Japan).
Preparation of plasmas containing emicizumab
Emicizumab at the indicated concentrations was incubated for 30 min at 37°C with FVIII-deficient plasma, and with PNP or FV-deficient plasma preincubated with anti-FVIII inhibitor polyclonal antibody (polyAb) at a final concentration (f.c.) of 16 Bethesda units (BU)/ml (expressed as FVIIIdepleted plasma). We confirmed that no FVIII activity was detected in the FVIII-depleted plasma by using the recently our established assay with clot waveform analysis .
TF/Elg-triggered thrombin generation assays (TGA)
Emicizumab mimics FVIIIa, and although the enhancing effects of the antibody appear too rapidly using contact activator (Elg)-triggered TGA, those using tissue factor (TF)-triggered TG could be less sensitive (Kitazawa et al, 2012) . Therefore, TGA were performed using a previously established protocol that was modified to reflect both pathways of intrinsic and extrinsic coagulation by utilizing a TF trigger (1 pmol/l) with Elg (0Á3 lmol/l) and PL vesicles (4 lmol/l) (Matsumoto et al, 2009) . Briefly, 20 ll trigger reagent (TF/ PL/Elg) was mixed with 80 ll test plasma in microtitre plates (ThermoLab System, Helsinki, Finland). The plates were placed in the fluorometer, and the assay initiated by the addition of 20 ll 100 mmol/l CaCl 2 and 5 mmol/l fluorogenic substrate. The development of fluorescent signals was monitored at 8-s intervals using Fluoroskan Ascent microplate reader (Thermo Electron Co., Waltham, MA, USA) with a 390 nm (excitation) and 460 nm (emission) filter set. TG (nmol/l) was calculated from fluorescent signals corrected by reference to the thrombin calibrator samples. Data analyses were performed using Thrombinoscope software. The parameters peak thrombin (peak-Th) and endogenous thrombin potential (ETP) were recorded. The percent inhibition of initial values at each data point was calculated as follows; [(value with APC(À) À value with APC(+) in the presence of emicizumab)/(value with emicizumab (+) À value with emicizumab (À) in the absence of APC)] 9 100.
FVIIIa degradation assay
FV cofactor activity of APC was measured in a FVIIIa degradation assay as previously described (Shen & Dahlb€ ack, 1994; Nogami et al, 2014) with minor modifications. FVIII (10 nmol/l) and PL (20 lmol/l) were activated by thrombin (5 nmol/l) for 1 min, and the reaction terminated with the addition of hirudin (2Á5 l/ml). The FVIIIa or emicizumab (20 lg/ml) was then incubated for 20 min with APC at various concentrations, PS (1Á25 nmol/l) and FV (1 nmol/l). Aliquots of the reaction mixtures were diluted 9-fold prior to incubation with FIXa (2 nmol/l) and FX (200 nmol/l) for 1 min. The rates of FXa generation were measured after the addition of specific chromogenic substrate S-2222 using a Labsystems Multiskan Multisoft microplate reader at 405 nm (Labsystems, Helsinki, Finland) . Measurements in the absence of APC were regarded as control, and FX generation was quantified after subtracting the control value.
Data analysis
Data are presented as the average and standard deviation (SD). Data analysis was performed using Microsoft Excel software. Significant differences were determined by the Wilcoxon t-test and Mann-Whitney U-test. P-values <0Á05 were considered as statistically significant.
Results
APC down-regulates emicizumab-driven haemostatic potential independent of FVIIIa
Thrombin generation mediated by emicizumab in FVIII-deficient plasma and in FVIII-depleted plasma were initially confirmed utilizing TGA triggered by low concentrations of both TF and Elg as described in Materials and methods. Emicizumab facilitated TG dose-dependently in the absence of FVIII ( Fig 1A) in a manner similar to that reported earlier (Muto et al, 2014) . Close to normal levels of peak-Th were observed at concentrations of emicizumab ranging from 60 to 120 lg/ml, and a normal ETP was recorded at 10 to 120 lg/ml emicizumab (data not shown). The experiments using FVIII-depleted PNP, prepared artificially by the addition of anti-FVIII polyAb (f.c. 16 BU/ml) demonstrated a similar enhancing effect of emicizumab to that seen with natural FVIII-deficient plasma (Fig 1B) .
The effects of APC on FVIIIa-independent TG mediated by emicizumab (30 lg/ml) were determined after incubation with various concentrations of APC (0-16 nmol/l). APC significantly depressed emicizumab-driven TG in FVIII-deficient plasma in a dose-dependent manner (Fig 2A-a) , although the TG levels even at the maximum concentrations of APC employed did not fall to those seen in FVIII-deficient plasma without emicizumab (Fig 2A-b) . Peak-Th and ETP were decreased by 60Á1% and 55Á9%, respectively in the presence of APC (8 nmol/l) in FVIIIdeficient plasma with emicizumab (Fig 2A-b) . Similarly, APC dose-dependently decreased emicizumab-driven TG in FVIII-depleted plasma (Fig 2B-a) . The peak-Th and ETP with APC (8 nmol/l) in the FVIII-depleted plasma with emicizumab were decreased by 53Á4% and 41Á1%, respectively (Fig 2B-b) . On the other hand, in the FVIII-driven TG assay using PNP, APC (e.g. 8 nmol/l) decreased the Peak-Th and ETP by 16Á9% and 19Á4%, respectively, in case of the TF/Elg triggering conditions ( Figure S1 ), supporting that APC-mediated down-regulation of emicizumab-driven TG appeared unlikely to be inferior to that of FVIII-driven TG.
FV cofactor activity to promote APC/PS activity does not contribute to down-regulation of the emicizumabmediated coagulation
The mechanism of APC-mediated inactivation of haemostasis in FVIII-deficient plasmas supplemented with emicizumab was further investigated in the FVIIIa degradation assay based on FXa generation as described in Materials and methods (Shen & Dahlb€ ack, 1994; Nogami et al, 2014) . This assay was used principally to evaluate the contribution of FV cofactor activity to APC/PS-catalysed inactivation of FVIIIa. FVIIIa-dependent FXa generation was significantly decreased by the presence of APC/PS and FV (Fig 3) . However, FVIIIa-independent FXa generation in the presence of emicizumab was unaffected by the presence of APC/PS and FV, indicating that FV cofactor activity played an insignificant role in the inhibitory mechanism. In conjunction with the evidence that APC depressed FVIIIa-independent, emicizumab-driven TG (Fig 2) , it appeared, therefore, that the APC-induced down-regulation of TG mediated by emicizumab in the absence of FVIIIa was accomplished by direct inactivation of FVa.
The role of FV/FVa in APC-induced down-regulation of emicizumab activity
The APC-mediated down-regulation of emicizumab-driven TG in FVIII-deficient plasma was attributed to APC-induced inactivation of FVa. To further investigate the role of FV/ FVa in APC-induced down-regulation of emicizumabmediated TG, we preincubated FV-deficient plasma with anti-FVIII polyAb (FVIII-depleted FV-deficient plasma) together with various concentrations of exogenous pd-FV. In the complete absence of FV, TG was not detected even in the presence of emicizumab. The addition of exogenous FV, however, promoted emicizumab-driven TG dose-dependently. The presence of FV at the lowest levels (1Á8 nmol/l; corresponded to~5 iu/dl in plasma) employed with emicizumab, provided sufficient stimulus for TG (Fig 4A) .
The function of FV/FVa as a substrate for APC catalytic activity in these circumstances was further investigated. Various concentrations of APC were added to FVIII-depleted FVdeficient plasma after incubation with emicizumab together with various concentrations of pd-FV. APC dose-dependently decreased the parameters of peak-Th and ETP. This dosedependent inhibitory pattern, however, was inversely related to the concentration of FV (Fig 4B) . Taken together, these results suggested that the presence of FV/FVa had an essential role in emicizumab-driven TG, and significantly contributed to the APC-induced braking mechanism in the absence of FVIII at all levels of FV.
Emicizumab-dependent TG in FVIII-depleted FV Leiden plasma
A specific point mutation in the F5 gene, Arg506Gln (R506Q; FV Leiden ) is a major cause of APC resistance (Bertina et al, 1994; Dahlb€ ack, 2016) , and the loss of the APC cleavage site at this site results in complete impairment of FV cofactor activity for APC in the FVIIIa inactivation process (Bertina et al, 1994) . Therefore, our experiments on APC-catalysed inhibition of emicizumab-driven TG were modified to investigate reactions in native FV Leiden plasma (Fig 5A-a) and in FV Leiden plasma incubated with anti-FVIII polyAb (FVIII-depleted FV Leiden plasma) (Fig 5A-b) . Control experiments without APC showed that the peak-Th in FVIIIdepleted FV Leiden plasma incubated with emicizumab (30 lg/ml) was lower than that in FV Leiden plasma. In the presence of APC, TG was reduced to a greater extent with emicizumab- supplemented FVIII-depleted FV Leiden plasma than native FV Leiden plasma. The down-regulation potential represented by inhibition of peak-Th and ETP in the presence of APC (e.g. 8 nmol/l) was greater by~5-fold and~3-fold, respectively (Fig 5B) , although the TG levels even at the maximum concentrations of APC employed did not fall to those in FVIII-depleted FV Leiden without emicizumab (Fig 5B) . Precise comparisons of these effects on APC-induced down-regulation were difficult, however, especially because of the difference in TG level between emicizumab-mediated FVIII-depleted FV Leiden and native FV Leiden , observed in the control experiments. Nevertheless, the results suggested that the moderating effect of APC on emicizumab-driven coagulation activity remained evident with FVIII-depleted FV Leiden , and that the dominant role of FVa in emicizumab-driven coagulation activity in the absence of FVIII was maintained even in the presence of the mutation at the Arg506 cleavage site.
Discussion
Activated protein C in the presence of PS moderates haemostasis by the following reactions -(i) direct inactivation of FVa, (ii) direct inactivation of FVIIIa and (iii) FVIIIa inactivation dependent on FV cofactor activity (Dahlb€ ack, 2016) . Investigations using traditional models are hampered, however, by the central effects of FVIIIa on coagulation techniques. The regulation and balancing of the different mechanisms related to APC function, therefore, remain poorly understood. Although our findings are solely based on information obtained from TGA, this calibrated technique does offer a suitable means for evaluating dynamic, APC-mediated anticoagulation reactions that progress simultaneously with coagulation following initial TG. In the present study, we have focused on APC-related down-regulation in the presence of emicizumab, a FVIIIa-mimetic anti-FIXa/ FX bispecific antibody that promotes TG in the absence of functional FVIII (Kitazawa et al, 2012; Sampei et al, 2013) . APC strongly limited emicizumab-driven TG by inactivating FVa, even in the absence of FVIII. Our results further suggested that this inhibition of emicizumab-mediated haemostasis in the absence of FVIII/FVIIIa possibly followed site-specific cleavage of FV. The findings demonstrated for the first time that direct inactivation of FVa, targeted by APC, significantly contributed to haemostatic down-regulation (pathway I as above) even in FVIII-deficient plasma.
Activated protein C-regulated haemostasis is generally assessed using TF-triggered TGA (Castoldi et al, 2004; Bos et al, 2005; Pezeshkpoor et al, 2016) , and our results utilizing TF/Elg-triggered TGA require further investigation. Nevertheless, emicizumab is known to mimic FVIIIa cofactor function rather than native FVIII, and the results of TF-triggered TGA, reflecting the extrinsic coagulation pathway, have demonstrated low sensitivity to the enhancing effect of the bispecific antibody, whilst Elg-triggered TGA, reflecting the intrinsic coagulation pathway, are likely to occur too rapidly for detecting emicizumab-mediated TG (Muto et al, 2014) . Our choice of the TF/Elg-triggered TGA was based, therefore, on our previously established protocol, modified to reflect both extrinsic and intrinsic mechanisms (Matsumoto et al, 2009) . We have also more recently determined the usefulness of the TF/Elg-trigger reagent for monitoring emicizumab using TGA and other global coagulation assays including clot waveform analysis (CWA) .
In this context, the concentrations of APC required for the anticoagulant effects in the present study were greater than had been previously published (Castoldi et al, 2004; Bos et al, 2005; Nogami et al, 2014; Pezeshkpoor et al, 2016) . These discrepancies could have been due to the use of difference of trigger reagents. Our additional experiments on APC regulation of TG in PNP illustrated that the reactivity to APC in Elg-triggered and TF/Elg-triggered TGA was lower than that in TF-triggered TGA ( Figure S1 ). The peak-Th levels in the two former assays were higher than that in the latter assay. It could have been expected, therefore, that the same concentration of APC might have had a different sensitivity depending on the rate and extent of the procoagulant reactions in the early stages of TG, and that assessment of APC reactions would fundamentally depend on the properties of different trigger reagents. The concentration of APC found at the sites of vascular injury would be much higher than plasma concentration due to the concentrated APC at the local sites of vascular injury, but the precise concentration of APC at local sites is unclear.
FV Leiden (Arg506Gln) has been well described as a prothrombotic mutation characterized by resistance to APC in 2-5% of the Caucasian population (Rees et al, 1995; Rees, 1996) . The defect is associated with the loss of cleavage at Arg506, resulting in the impairment of cofactor activity, despite the presence of an intact cleavage site at Arg306 that is essential for direct inactivation by APC (Nicolaes et al, 1995) . Our findings that TG in FVIIIdepleted FV Leiden plasma supplemented with emicizumab was down regulated by APC more than that with native FV Leiden plasma, indicated that APC-catalysed FVa inactivation was pivotal in these circumstances. Patients with an inherited, combined deficiency of FVIII and FV Leiden have also been identified, but whether the clinical phenotype in these cases would be expected to be prothrombotic or haemophilic is controversial (Lee et al, 2000; Franchini & Lippi, 2010) . Nevertheless, our data confirmed that direct FVa inactivation could support APC activity under these conditions (pathway I), suggesting that emicizumab would well receive the negative feedback from the PC system in these conditions. Emicizumab is a humanized, bispecific antibody that spatially relocates FIXa and FX to the optimal position on the activated platelet surface and facilitates haemostatic function of the tenase complex in the absence of FVIIIa (Sampei et al, 2013) . One of the concerns regarding the use of emicizumab in haemophilia A patients is the negative feedback regulation of excessive haemostatic enhancement. We have recently clarified that the presence of emicizumab is irrelevant to the action of antithrombin and TF pathway inhibitor in vitro (Noguchi-Sasaki et al, 2018) . Together with the results of this study, this indicates that the major negative feedback system would work in emicizumab-mediated coagulation.
Some limitations in the present study remain to be considered, however. One is that the TGA only was used in a series of experiments because it was difficult to evaluate emicizumab-related studies by the other assays (activated partial thromboplastin time-based assay, etc.). Secondly, the concentration of emicizumab (30 lg/ml) employed in this study was slightly low relative to the therapeutic plasma concentrations expected to be clinically applicable (40-60 lg/ ml) (Oldenburg et al, 2017) . However, it would not be so unreasonable to clarify the mechanism on APC-mediated down-regulation when considering the clinical situation with emicizumab. Nevertheless, this is the first report to characterize critical APC-related interactions in mechanisms of haemostasis in the absence of FVIIIa associated with the use of emicizumab. We have identified specific mechanism(s) of APC-catalysed haemostatic control, including the unique property of focusing on FVa as a target for inactivation in the absence of FVIII. We hope that our data could provide important information on the potentially significant regulation of haemostasis in patients with haemophilia A treated with emicizumab.
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